Loading…
Global Life Technologies Corp. distributed Nozin® Nasal Sanitizer® as an unapproved new drug in violation of section 505(a) of the FD&C Act and as a misbranded drug under section 502(ee), based on FDA's review of the company's website and social media channels in October 2023. The product was marketed with claims that it functions as a topical antiseptic to kill pathogenic bacteria in the nasal passages, thereby qualifying it as a drug requiring FDA approval that the company had not obtained. The company's labeling and promotional materials on their website and social media platforms (Facebook and Twitter) made disease prevention and treatment claims that established the unapproved intended use.